Genasense needs another trial in leukaemia
This article was originally published in Scrip
Executive Summary
Genta will need to conduct another trial of its novel antisense anticancer Genasense (oblimersen sodium) in chronic lymphocytic leukaemia (CLL) before the US FDA can approve the drug for this indication, the company said.